Pneumoperitoneum Preconditioning for the Prevention of Renal Function After Laparoscopic Partial Nephrectomy

Sponsor
Nanjing First Hospital, Nanjing Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03822338
Collaborator
(none)
86
1
2
20.8
4.1

Study Details

Study Description

Brief Summary

The present study is designed to investigate the short-term and long-term renoprotective role of pneumoperitoneum preconditioning in patients undergoing laparoscopic partial nephrectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pneumoperitoneum preconditioning
  • Procedure: Sham-Pneumoperitoneum preconditioning
N/A

Detailed Description

Renal ischemia reperfusion injury (IRI) is an inevitable event in patients undergoing laparoscopic partial nephrectomy (LPN), which can obviously affect the post-operational renal function. Pneumoperitoneum preconditioning (PP) is a promising strategy to render a protective effect on kidney, which has been already confirmed in some clinical settings. This study is designed as a randomized, prospective, double-blind and parallel controlled clinical trial to assess the short-term and long-term renoprotective role of pneumoperitoneum preconditioning in patients undergoing laparoscopic partial nephrectomy, and observe its effect on the other abdominal organs. Patients with renal tunours and willing to accept elective LPN will be screened as eligible participants. The investigators aim to enroll 86 subjects. Patients randomized to the treatment arm will receive PP consisted of three cycles of 5 min insufflation and 5 min desufflation before PLN, while the control arm receive a sham operation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
86 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Pneumoperitoneum Preconditioning for the Prevention of Renal Function After Laparoscopic Partial Nephrectomy: a Double-blind Randomized Controlled Trial
Anticipated Study Start Date :
Aug 6, 2019
Anticipated Primary Completion Date :
Feb 1, 2021
Anticipated Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pneumoperitoneum preconditioning group

Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.

Procedure: Pneumoperitoneum preconditioning
Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.

Sham Comparator: Control group

Participants in the control group will receive the same placement of the veress but without insufflation and subsequent desufflation.

Procedure: Sham-Pneumoperitoneum preconditioning
Sham-Pneumoperitoneum preconditioning consists of three cycles without insufflation and subsequent desufflation. The whole duration will also last 30 min.

Outcome Measures

Primary Outcome Measures

  1. The absolute change in glomerular filtration rate (GFR) [changes from baseline and postoperative 1, 6 months]

    Unilateral and overall GFR detected by 99mTc-DTPA renal scintigraphy.

  2. The absolute change in the level of serum Cystatin C (Cys C) [changes from baseline and 12, 24, 48 hours after desufflation]

    The absolute change in the level of serum Cys C after desufflation.

Secondary Outcome Measures

  1. The level of serum creatinine (SCr) [Baseline; 12, 24, 48 hours, and 1, 6 months after desufflation]

    The absolute change in the level of serum SCr after desufflation.

  2. Estimated glomerular filtration rate (eGFR) [Baseline; 12, 24, 48 hours, and 1, 6 months after desufflation]

    eGFR will be calculated by a combined formula.

  3. The level of alanine transaminase (ALT) [Baseline; 12, 24, 48 hours, and 1, 6 months after desufflation]

    Serum markers for detecting the insults of the liver.

  4. The level of serum amylase [Baseline; 12, 24, 48 hours, and 1, 6 months after desufflation]

    Serum markers for detecting the insults of the pancreas.

  5. The level of intestinal fatty acid binding protein (I-FABP) [Baseline; 12, 24, 48 hours, and 1, 6 months after desufflation]

    Serum markers for detecting the insults of the intestine.

Other Outcome Measures

  1. Duration of postoperative hospital stay [6 months following surgery]

  2. Incidence of adverse events [6 months following surgery]

  3. Rate of mortality [6 months following surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and female patients aged 18 years and older;

  • Patients with renal tumours (whether benign or malignant) and accept laparoscopic partial nephrectomy as the surgical method;

  • The renal tumor must be stage T1a (assessed by MRI/CT), and tumor≤4cm in diameter;

  • Unilateral renal tumour, and another contralateral renal function reveal normal (renal function >40% as determined by radionuclide scintigraphy);

  • Patients volunteer for this study and provided written informed consent.

Exclusion Criteria:
  • Large tumour (tumor>4cm in diameter);

  • Severe renal insufficiency (glomerular filtration rate, GFR<30 ml/min/1.73m2) or needing preoperative dialysis (hemodialysis or peritoneal dialysis);

  • Patients severe cardiopulmonary dysfunction;

  • Pregnancy Women;

  • Patients with other malignant tumours;

  • Patients who have had a renal transplantation;

  • Patients with a history of other abdominal viscera operations within one year (open or under laparoscope);

  • American Society of Anesthesiologists (ASA)>Ⅲ.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nanjing First Hospital Nanjing Jiangsu China 210006

Sponsors and Collaborators

  • Nanjing First Hospital, Nanjing Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ruipeng Jia, Study Chair, Nanjing First Hospital, Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT03822338
Other Study ID Numbers:
  • NFH20180205
First Posted:
Jan 30, 2019
Last Update Posted:
Jun 3, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ruipeng Jia, Study Chair, Nanjing First Hospital, Nanjing Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 3, 2019